Steroid-refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort

Inflammatory Bowel Diseases

Volumn 14, Issue 3, 2008, Pages 347-352

  Aceituno Quintanilla, Montserrat ^a   García Planella, Esther ^b   Heredia, Carolina ^a   Zabana, Yamile ^b   Feu, Faust ^a   Domènech, Eugeni ^b   Gassull, Miguel Àngel ^b   Panés, Julián ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cyclosporine; Predictive factors; Steroid resistant; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN; PREDNISOLONE; STEROID;

ADULT; ARTICLE; COHORT ANALYSIS; COLON RESECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HERPES SIMPLEX; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; THRUSH; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

ADULT; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PREDNISOLONE; PREVALENCE; PROSPECTIVE STUDIES; SPAIN;

EID: 41149161165     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20322     Document Type: Article

References (24)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299-315.
2. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985;89:1005-1013.
3. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-1845.
5. Durai D, Hawthorne AB. Review article: how and when to use cyclosporin in ulcerative colitis. Aliment Pharmacol Ther. 2005;22:907-916.
6. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73-78.
7. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol. 1996;91:2498-2499.
8. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol. 1998;10:411-413.
9. Van AG, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025-1031.
10. Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis. 1998;4:276-279.
11. Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol. 2001;36:610-614.
12. Daperno M, Sostegni R, Scaglione N, et al. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis. 2004;36:21-28.
13. Campbell S, Travis S, Jewell D. Cyclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005;17:79-84.
14. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
15. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811.
16. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079-1087.
17. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831-835.
18. Domenech E, Garcia-Planella E, Bernal I, et al. Azathioprine without oral cyclosporin in the long-term maintenance of remission induced by intravenous cyclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2002;16:2061-2065.
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
20. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-910.
21. Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:273-279.
22. Moskovitz DN, Van AG, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760-765.
23. Cacheux W, Lemann M, Marteau P, et al. Predictive factors of response to cyclosporine (CsA) in severe steroid-refractory ulcerative colitis (SSRUC). Gastroenterology. 2006;A-143.
24. Rowe FA, Walker JH, Karp LC, et al. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol. 2000;95:2000-2008.